We consent to the reference to our firm under the caption “Experts” in this Registration Statement (Form S-3) and related Prospectus of Sangamo Therapeutics, Inc. for the registration of common stock, preferred stock, debt securities and
warrants and to the incorporation by reference therein of our reports dated March 13, 2024, with respect to the consolidated financial statements of Sangamo Therapeutics, Inc., and the effectiveness of internal control over financial reporting of
Sangamo Therapeutics, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.